New MS drug trial aims to reduce brain lesions and relapses
NCT ID NCT07321093
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called BCD-281 in people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces brain lesions and relapse rates better than the current standard drug. About 292 adults aged 18-55 with mild to moderate disability are being recruited. Participants will receive either BCD-281 or the reference drug, and researchers will monitor their safety and disease activity over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
LLC "Medis"
RECRUITINGNizhny Novgorod, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your own blood cells tame MS? early trial shows promise
- Hidden hunger in MS: new study probes link between malnutrition and disability
- Could a gut bacteria byproduct tame MS?
- MS patients on ozanimod: how long does treatment last?
- Could stem cells ease MS symptoms? new trial tests hope
- MS breakthrough? trial tests if older patients can ditch heavy drugs